Literature DB >> 21540457

GM-CSF-based fusion cytokines as ligands for immune modulation.

Patrick Williams1, Jacques Galipeau.   

Abstract

Chromosomal translocations that combine distinct functional domains of unrelated proteins are an experiment in nature. They demonstrate how endogenous regulatory checkpoints can be overridden by altered cell biochemistry, informing a means to engineering an aberrant signal that the cell is incapable of counterregulating. Thus, our laboratory and others have synthesized fusions of GM-CSF with peptides, ILs, and chemokines, which we have termed fusokines, with the aim of inducing an enhanced immune response against cancer, aiming to overcome the maladapted biological processes causing disease. In doing so, we found that these fusokines did not behave as merely the sum of their natural unfused counterparts, but as entirely novel ligands co-opting their cognate receptor to communicate a unique message to responsive cellular targets. In this review, we discuss how fusion proteins combining different bioactive ligands can alter immune responses and briefly discuss the regulatory pathways that they circumvent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540457     DOI: 10.4049/jimmunol.1003699

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.

Authors:  Spencer Ng; Jacques Galipeau
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

Review 2.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

3.  Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.

Authors:  Jiusheng Deng; Shala Yuan; Andrea Pennati; Jordan Murphy; Jian Hui Wu; David Lawson; Jacques Galipeau
Journal:  Cancer Res       Date:  2014-06-17       Impact factor: 12.701

4.  FIST, a sword and shield fusokine for cancer immunotherapy.

Authors:  Claudia Penafuerte; Jacques Galipeau
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

5.  Localized interleukin-12 delivery for immunotherapy of solid tumours.

Authors:  Louis Z Wei; Yixin Xu; E Megan Nelles; Caren Furlonger; James C M Wang; Marco A Di Grappa; Rama Khokha; Jeffrey A Medin; Christopher J Paige
Journal:  J Cell Mol Med       Date:  2013-11-19       Impact factor: 5.310

6.  Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.

Authors:  Felicity C Stark; Michael J McCluskie; Lakshmi Krishnan
Journal:  Vaccines (Basel)       Date:  2016-11-17

Review 7.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

8.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

9.  A fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity.

Authors:  Pingxin Li; Shala Yuan; Jacques Galipeau
Journal:  PLoS One       Date:  2013-07-01       Impact factor: 3.240

10.  Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives.

Authors:  Andrea Pennati; Jiusheng Deng; Jacques Galipeau
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.